Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 2/20 | 0.65 |
| ▸ | HTT | P42858 | 2/20 | 0.65 |
| ▸ | AR | P10275 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19677336 | 0.94 | AR (0.74) | HIF1AHTTARKMT2AMAPT | |
| SCHEMBL18821922 | 0.94 | HTT (0.58) | HIF1AHTTARKMT2AMAPT | |
| SCHEMBL13513185 | 0.94 | HTT (0.58) | HIF1AHTTARKMT2AMAPT | |
| SCHEMBL12267331 | 0.94 | AR (0.74) | HIF1AHTTARKMT2AMAPT | |
| SCHEMBL17694782 | 0.94 | HTT (0.58) | HIF1AHTTARKMT2AMAPT | |
| SCHEMBL14695443 | 0.92 | AR (0.76) | HIF1AHTTARKMT2AMAPT | |
| SCHEMBL14694748 | 0.92 | AR (0.76) | HIF1AHTTARKMT2AMAPT | |
| SCHEMBL14694747 | 0.92 | AR (0.76) | HIF1AHTTARKMT2AMAPT | |
| SCHEMBL14695376 | 0.92 | AR (0.76) | HIF1AHTTARKMT2AMAPT | |
| SCHEMBL14695206 | 0.92 | AR (0.76) | HIF1AHTTARKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9862667-B2 | Diglycidic ether derivative therapeutics and methods for their use | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2018-01-09 | — | — | US | disclosed |
| EP-3252032-A1 | DIGLYCIDIC ETHER DERIVATIVE THERAPEUTICS AND METHODS FOR THEIR USE | British Columbia Cancer Agency Branch (CA) | 2017-12-06 | — | — | EP | disclosed |
| EP-2307342-B1 | DIGLYCIDIC ETHER DERIVATIVE THERAPEUTICS AND METHODS FOR THEIR USE | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2017-06-21 | — | — | EP | disclosed |
| US-20170121261-A1 | DIGLYCIDIC ETHER DERIVATIVE THERAPEUTICS AND METHODS FOR THEIR USE | THE UNITED STATES GOVERNMENT | 2017-05-04 | — | — | US | disclosed |
| US-20170121261-A1 | DIGLYCIDIC ETHER DERIVATIVE THERAPEUTICS AND METHODS FOR THEIR USE | THE UNITED STATES GOVERNMENT | 2017-05-04 | — | — | US | disclosed |
| US-20130245129-A1 | DIGLYCIDIC ETHER DERIVATIVE THERAPEUTICS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2013-09-19 | — | — | US | disclosed |
| US-20130245129-A1 | DIGLYCIDIC ETHER DERIVATIVE THERAPEUTICS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2013-09-19 | — | — | US | disclosed |
| US-20110230556-A1 | Diglycidic Ether Derivative Therapeutics and Methods for Their Use | THE UNITED STATES GOVERNMENT | 2011-09-22 | — | — | US | disclosed |
| US-20110230556-A1 | Diglycidic Ether Derivative Therapeutics and Methods for Their Use | THE UNITED STATES GOVERNMENT | 2011-09-22 | — | — | US | disclosed |
| WO-2010000066-A1 | DIGLYCIDIC ETHER DERIVATIVE THERAPEUTICS AND METHODS FOR THEIR USE | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170121261-A1 | DIGLYCIDIC ETHER DERIVATIVE THERAPEUTICS AND METHODS FOR THEIR USE | UGCG, PTGFR, KLK3 | HIF1A 530/4885HTT 4813/4885AR 206/4885 |
| US-20130245129-A1 | DIGLYCIDIC ETHER DERIVATIVE THERAPEUTICS AND METHODS FOR THEIR USE | MAN2B2, UGCG, KLK3 | HIF1A 1235/4885HTT 4659/4885AR 179/4885 |
| US-20110230556-A1 | Diglycidic Ether Derivative Therapeutics and Methods for Their Use | MAN2B2, KLK3, UGCG | HIF1A 1200/4885HTT 4653/4885AR 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.